Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

This article presents a comprehensive overview of the molecular mechanisms underlying the anti-cancer properties of ICA, and further highlights recent progress in use of ICA in cancer research, ...

Dr. Waqqas Tai is a cancer doctor who often shares health advice online. He recently revealed what the five most "lethal" ...

A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...

This article presents a comprehensive overview of the molecular mechanisms underlying the anti-cancer properties of ICA, and further highlights recent progress in use of ICA in cancer research, ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

He noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...